Related Experiment Video
Updated: Mar 6, 2026
10:25
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
Published on: February 19, 2019
12.2K
Hepatitis B and concomitant hepatic steatosis
Chong Teik Lim1, Rajneesh Kumar1
1Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore.
Annals of Translational Medicine
|March 3, 2017
Summary
Non-alcoholic fatty liver disease (NAFLD) and Hepatitis B are increasingly common together in Asia. This review explores their complex molecular and clinical interactions, highlighting the need for further research into this dual diagnosis.
Area of Science:
- Hepatology
- Gastroenterology
- Epidemiology
Background:
- Hepatic steatosis (fatty liver disease) prevalence is rising in Asia, nearing Western levels.
- The co-occurrence of Hepatitis B virus (HBV) infection and hepatic steatosis is a growing clinical concern.
- Understanding the interplay between these two conditions is crucial for effective patient management.
Purpose of the Study:
- To review and synthesize current literature on the interaction between Hepatitis B and hepatic steatosis.
- To explore the molecular mechanisms underlying the combined effects of these diseases.
- To examine the clinical outcomes associated with concomitant Hepatitis B and hepatic steatosis.
Main Methods:
- Comprehensive literature search of relevant scientific databases.
- Systematic review and synthesis of existing research findings.
- Analysis of studies investigating molecular pathways and clinical data.
Main Results:
- The review identifies emerging patterns in the interaction between HBV and fatty liver.
- Evidence suggests potential synergistic or antagonistic effects at the molecular level.
- Clinical outcomes vary, influenced by factors such as viral load, steatosis severity, and host genetics.
Conclusions:
- The co-existence of Hepatitis B and hepatic steatosis presents a complex clinical challenge.
- Further research is essential to elucidate the intricate interactions and guide therapeutic strategies.
- A deeper understanding is needed to optimize treatment and improve prognoses for patients with both conditions.
More Related Videos
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
244
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
319
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
319
01:26Diseases of the Liver and Gallbladder
2.2K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
304
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
304
01:16Hepatic Drug Excretion: Influencing Factors
688
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
688
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
273
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
273